利奈唑胺治疗耐多药结核病的初步评价

Treatment Outcomes of Linezolid for Multidrug-resistant Tuberculosis： A Systematic Review and Meta-analysis

目的初步评价利奈唑胺治疗耐多药结核（MDR—TB）的有效性与安全性。方法检索Cochrane图书馆临床对照试验库、Pubmed、Embase、CBM、CNKI、Wanfang Data等电子数据库。对符合纳入标准的临床研究进行统计分析。结果共有7个国家的5个临床研究符合纳入标准。分析结果表明，含利奈唑胺的联合化疗方案治疗MDR—TB的合并成功率为82％（95％CI73％～89％）；治疗结果为失败、丢失或死亡的比例分别为2％、5％、11％。血液系统不良反应、神经毒性和胃肠道反应的发生率分别为32％、25％、6％。结论利奈唑胺对耐多药结核病有较好的疗效，但药物不良反应发生率较高。

Objective To evaluate the efficacy and safety of linezolid for treating multidrug resistant tuberculosis （MDR-TB）. Methods Cochrane Controlled Trials database, Pubmed, Embase, CBM, CNKI, Wanfang Data and other electronic databases were searched. Clinical studies matched the inclusion criteria would be analysed statistically. Results A total of five clinical studies met the inclusion criteria in seven countries. The results showed that the mean proportion of patients achieving treatment success was 82%（95% CI 73% - 89%） ; the mean proportion of patients whose outcome were treatment failure, default and death were 2%, 5% and 11%, respectively. The incidence rate of adverse events in hematopoietic system and neurotoxicity and gastrointestinal system were 32%, 25%, 6%, respectively. Conclusion Linezolid against MDR-TB has a good efficacy, but the incidence of adverse events is higher.